Inside a Pharma Bet: From Science to Revenue

Six layers connect a scientific discovery to a company's bottom line — and the same logic explains almost any major pharma decision in the headlines.

Prepared by Richstorm.co

Key Takeaways

• Every major pharma decision, from R&D bets to manufacturing and pricing, sits somewhere on a six-layer stack running from scientific origin to eventual revenue.

• Whether a bet starts from an unmet medical need or an already-proven platform determines how narrow or expansive the resulting company strategy becomes.

• Manufacturing complexity is not just an operations question. It directly sets the margin on the revenue the science eventually earns.

• Where and how a therapy actually reaches patients, not just where it is made, is its own strategic layer shaped by policy and payer negotiation.

• The same six-layer lens applies to reading any pharmaceutical company's strategy, not just the case study used here.

In 2026, Vertex Pharmaceuticals and CRISPR Therapeutics expect combined revenue from their jointly developed gene therapy Casgevy, and Vertex's newly approved pain medication Journavx, to reach roughly $500 million, nearly triple what Casgevy alone brought in the prior year. That single number is really the visible endpoint of a six-layer stack of decisions that started over a decade earlier with a question no earnings call ever answers directly: given uncertain science and enormous capital requirements, where does a company concentrate its bets, and where does it deliberately spread the risk?

This framework uses Casgevy, the first CRISPR-based gene therapy ever approved, as a running case study. But the six layers apply to almost any pharmaceutical company's strategy, not just this one.

Layer 1 — Where the Bet Starts: Need or Technology

Every pharma bet begins in one of two places. Either a documented gap in patient care already exists and a company goes looking for a mechanism to fill it, or a scientific capability matures on its own and the company goes looking for a disease it happens to fit.

Casgevy is about as clean an example of the second pattern as exists in modern pharma. CRISPR/Cas9 gene editing was recognized with the Nobel Prize in Chemistry in 2020, years after the core discovery, based on research demonstrating a general-purpose way to edit DNA with precision. The disease application came after the platform: CRISPR Therapeutics and Vertex established their research collaboration in 2015, specifically to discover and develop therapies using CRISPR/Cas9 to address the genetic causes of disease broadly, well before sickle cell disease and beta thalassemia became the specific, proven applications.

Contrast that with a need-pull case: a disease with a well-documented treatment gap that multiple companies race to fill because everyone already agrees the gap exists. Sickle cell disease itself had been an unmet need for decades before CRISPR technology existed at all. What Casgevy represents is a validated technology finally meeting a need that had been waiting for a good enough mechanism to arrive.

Neither path is inherently better, but knowing which one a company is following says a lot about what it does next. Technology-push companies tend to keep hunting for new indications for the same platform. Need-pull companies tend to go deep on a single disease area instead.

Layer 2 — What You're Actually Betting On

Once the origin story is set, a company effectively decides how concentrated its exposure will be. There are three distinct bet sizes worth telling apart:

• Modality bets: owning a broad category across many programs, so no single failure sinks the company. This is closer to Vertex's posture: Casgevy sits alongside an established cystic fibrosis franchise and a newly approved non-opioid pain therapy, Journavx, spreading the company's fortunes across multiple modalities and disease areas.

• Platform bets: wagering that one company's proprietary engineering system beats its rivals within a shared modality. This is closer to CRISPR Therapeutics's position. Beyond Casgevy, the company is advancing a pipeline of in vivo gene editing candidates in cardiovascular, metabolic, and rare disease using its own lipid nanoparticle delivery platform, meaning its fortunes are far more concentrated in CRISPR-based editing succeeding broadly, not just Casgevy specifically.

• Single-asset bets: betting on one molecule clearing trials. This is the highest-variance layer, and the one most retail biotech investing actually happens at.

  The same underlying trend can represent very different risk profiles depending on which layer a given company sits in. Vertex and CRISPR Therapeutics are both exposed to Casgevy's success, but they are not making the same bet.

Layer 3 — Build, Buy, or License

A detail that surprises people: the platform almost never originates inside the company that eventually commercializes it at full scale. The foundational CRISPR/Cas9 science traces back to academic research by Jennifer Doudna and Emmanuelle Charpentier, work that later earned the Nobel Prize. CRISPR Therapeutics was built to commercialize that science, but even it did not carry Casgevy to market alone.

Under the companies' amended collaboration agreement, Vertex leads global development, manufacturing, and commercialization of Casgevy, while the two companies split profits and program costs 60/40. Vertex is the manufacturer and exclusive license holder. In effect, CRISPR Therapeutics supplied the foundational platform and target science; Vertex supplied the commercial-scale execution, manufacturing infrastructure, and payer relationships needed to actually sell a $2.2 million therapy at scale.

This layer is the zoomed-in version of the acquisition and partnership framework covered in our earlier piece, "The Acquirer's Playbook: How a Pharma VP Actually Chooses What to Buy," applied specifically to platform science.

Layer 4 — Making It at Scale

This is where science stops being the constraint and manufacturing takes over, and it is the layer with the most misunderstood economics.

Casgevy is a non-viral, ex vivo gene-edited cell therapy: a patient's own hematopoietic stem and progenitor cells are collected, shipped to a manufacturing facility where they are edited at a specific gene region, then shipped back and reinfused. Like autologous cell therapies more broadly, this process cannot be mass-produced in the traditional pharmaceutical sense. Every batch is a single patient's own cells, which is exactly the kind of process the industry has spent the last several years building automated, closed-system manufacturing platforms to standardize, since manual, open-step processing introduces variability, extends timelines, and raises contamination risk.

The return-on-investment logic here is worth stating plainly, because it is not primarily about labor savings. In pharma manufacturing broadly, a single product recall can exceed $100 million, and regulatory warning letters often carry tens of millions in remediation costs. Automation's real economic case in this category of therapy is as much about avoiding catastrophic quality failures, and about simply being able to run the process at all reliably, as it is about efficiency.

Casgevy's slow early rollout illustrates the cost of getting this layer wrong, or simply underestimating its difficulty. More than two years after its first approval, only a few hundred patients had been referred to treatment centers, with a much smaller number actually completing infusion. The bottleneck was not demand. It was the operational complexity of collecting, shipping, editing, and reinfusing cells reliably at scale.

Layer 5 — Where and Why Now

For a therapy like Casgevy, the equivalent of a facility decision is the rollout of Authorized Treatment Centers, the specific hospitals certified to collect and reinfuse patient cells, combined with the state-by-state and payer-by-payer fight over reimbursement. As of early 2026, 33 states and Washington, D.C. had joined the Centers for Medicare and Medicaid Services' Cell and Gene Therapy Access Model, which lets state Medicaid programs negotiate outcomes-based contracts for exactly this kind of therapy, since Medicaid covers a large share of the U.S. sickle cell disease population.

In other words, for a therapy this expensive and this operationally complex, availability is not just a manufacturing question, it is a payer-access and regulatory-model question layered on top of the science-and-manufacturing decision. A therapy can be fully approved and still take years to actually reach the patients it was built for, simply because the access infrastructure has to be built in parallel with the manufacturing infrastructure.

Layer 6 — How the Bet Pays Back

Every layer before this one is cost and risk. This is where, if everything works, it becomes return, and it carries its own internal logic.

Pricing power is not simply a function of clinical value; it depends on what payers will actually reimburse, and on how a therapy compares to its direct competitors. Vertex set Casgevy's list price at $2.2 million, notably the lowest of the two approved gene therapies for hemoglobin disorders, undercutting a competitor's $3.1 million therapy launched the same week. Once hospital conditioning, cell collection, and post-infusion monitoring are added, insurers often pay closer to $3 million per patient in total cost of care.

The revenue trajectory shows how long this kind of bet can take to pay off. Casgevy earned $10 million in 2024, its first full year on the market, then grew to $115.8 million in 2025, and is projected to grow further still in 2026. That multi-year ramp, not an instant payoff, is typical for therapies this operationally complex and this dependent on new payer infrastructure being built around them.

This is where the stack closes its loop back to Layer 4. Manufacturing reliability is not just an operations metric, it directly determines how fast a company can convert approved therapies into actual infusions and actual revenue. Casgevy's slow early ramp was a story about operational bottlenecks constraining a genuinely approved, genuinely reimbursed therapy, not about unresolved science or unwilling payers.

The Stack, Not the Snapshot

Read as a single story, Casgevy's climb from $10 million to a projected several hundred million dollars in annual revenue is really the visible endpoint of six separate decisions stacked on top of each other: where the science came from, how concentrated each partner's bet is, who owns the platform, how it gets made at scale, how it actually reaches patients, and how it eventually turns into profit.

The same six layers apply whether the headline is a landmark gene therapy approval or a five-person biotech's Phase 2 readout. The company and the numbers will change. The stack won't.